Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration

Blood

Volumn 93, Issue 6, 1999, Pages 2081-2088

  Rosenberg, Mireille ^a   Kingma, Wytske ^a   Fitzpatrick, Mary Anne ^a   Richards, Susan M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; GLUCOSYLCERAMIDASE;

ANTIBODY PRODUCTION; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME REPLACEMENT; FLUSHING; GAUCHER DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; SEROCONVERSION; TREATMENT OUTCOME; URTICARIA;

EID: 0033559287     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.6.2081.406k07_2081_2088     Document Type: Article

References (30)

1. Brady RO, Kanfer J, Shapiro D: The metabolism of glucocerebrosidase. I purification and properties of a glucocerebrosidase-cleaving enzyme from spleen tissue. J Biol Chem 340:39, 1965
2. Brady RO, Kanfer J, Shapiro D: The metabolism of glucocerebrosidase. II evidence of enzymatic deficiency in Gaucher disease. Biochem Biophys Res Commun 18:221, 1965
3. Beutler E, Grabowski GA: Gaucher disease, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease (ed 7). New York, NY, McGraw-Hill, 1995, p 2641
4. Grabowski A, Gatt S, Horowitz M: Acid β-glucosidase: Enzymology and molecular biology of Gaucher disease. Crit Rev Biochem Mol Biol 25:385, 1990
5. National Institute of Health Technology Assassement Conference Statement: Gaucher Disease: Current issues in diagnosis and treatment. Bethesda, MD, NIH, March 1995
6. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO: The uptake of naive and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun 81:1047, 1978
7. Barton NW, Brady RO, Dambrosia JM, DiBiseglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker, RI, Argoff CE, Grewal RP, Yu KT: Replacement therapy for inherited deficiency macrophage targeted glucocerebrosidase for Gaucher's Disease. N Engl J Med 324:1464, 1991
8. Richards S: Protein replacement therapy for genetic disease: Immunological considerations. Int Pediatr 8:17, 1993
9. Ross JM: Allergy to insulin. Pediatr Clin North Am 31:675, 1984
10. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R: Safety of recombinant deoxyribonucleic acid-derived growth hormone: The national cooperative growth study experience. J Clin Endocrinol Metab 81:1704, 1996
11. Kaplan SL, Underwood LE, August GP, Bell JJ, Blethen SL, Blizzard RM, Brown DR, Foley TP, Hintz RL, Hopwood NJ, Johanson AJ, Kirkland RT, Plotnick LP, Rosenfeld RG, Van Wyk JJ: Clinical studies with DNA derived methionyl-human growth hormone in growth hormone deficient children. Lancet 1:697, 1986
12. Roberts HR: Factor VIII inhibitors. Prog Clin Biol Res 150:1, 1984
13. Figlin RA, De Kernion JB, Mukalel E, Palleroni AV, Itri LM, Sarna GP: Recombinant interferon alpha-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 6:1604, 1988
14. Knobler RL, Greenstein JI, Johnson KP, Liblin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC, Williams GJ, Yoshizawa CN: Systemic recombinant human interferon β treatment of relapsing multiple sclerosis: Pilot study analysis and six year follow-up. J Interferon Res 13:333, 1993
15. Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childa A, Wolfe SN, Mier JW: The development of anti-interleukin 2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 6:481, 1986
16. Van Gils FC, Westerman Y, Visser TP, Burger H, Van Leen RW, Wagemaker G: Neutralizing antibodies during treatment of homologous nonglycosylated IL-3 in rhesus monkeys. Leukemia 8:648, 1994
17. Kato Y, Yamamoto M, Ikenaga T, Shintome T, Asano M, Okabe M, Hara T, Deguchi T: In vivo effect of human granulocyte stimulating factor derivatives on hematopoiesis in primates. Acta Haematol 86:70, 1991
18. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastores G: Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13:146, 1993
19. Wussow PV, Jakschies D, Freund M, Hehlmann R, Brockhaus F, Hochkeppel H, Horisberger M, Deicher H: Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Br J Haematol 78:210, 1991
20. Crowe JS, Gewert DR, Barber KA, Lewis AP, Sims MJ, Davies SL, Salom CL, Wood J, Thomas HC, Thursz M, Lok AS: Interferon (IFN) alpha 2 genotype analysis of chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy. J Infect Dis 169:875, 1994
21. Richards SM, Olson TA, McPherson JM: Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocrebrosidase. Blood 82:1402, 1993
22. Ponce E, Moskovitz J, Grabowski G: Enzyme therapy in Gaucher disease type 1: Effect of neutralizing antibodies to Acid β-glucosidase. Blood 90:43, 1997
23. Brady RO, Murray GJ, Olivier KL, Leitman SF, Sneller MC, Fleisher TA, Barton NW: Management of neutralizing antibody to Ceredase in a patient with type III Gaucher disease. Pediatrics 100:111, 1997
24. Ludwig J: Current Methods of Autopsy Practice. Philadelphia, PA, Saunders, 1979
25. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker T, Niklason LT, Hill SC, Miller SPF, Brady RO, Barton NW: Enzyme replacement therapy for Gaucher disease, skeletal responses to macrophage targeted glucocrebrosidase. Pediatrics 96:629, 1995
26. Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring-Lambert B, Reville P, Pinguet M: Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38:577, 1995
27. Frasier SD, Aceto T, Hayles AB, Parker ML, Meyer-Bahlburg HFL: Collaborative study of the effects of human growth hormone in growth hormone deficiency. II Development and significance of antibodies to human growth hormone during the first year of therapy. J Clin Endicrinol Metab 38:14, 1974
28. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet 349:521, 1997
29. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Vrolix M, De Man F, Benit E, Muydermans L, Collen D, Van de Werf F: A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STRAR trial Group. Circulation 92:2044, 1995
30. Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH: Loss of interferon antibodies during prolonged continuous interferon-α 2a therapy in hairy cell leukemia. Blood 77:792, 1991